共 50 条
- [1] Is Bevacizumab Effective for Reducing Epistaxis in Hereditary Hemorrhagic Telangiectasia? [J]. LARYNGOSCOPE, 2017, 127 (02): : 289 - 290
- [2] The Effect of Bevacizumab (Avastin) Treatment on Epistaxis in Hereditary Hemorrhagic Telangiectasia [J]. LARYNGOSCOPE, 2009, 119 (05): : 988 - 992
- [3] Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review [J]. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2019, 128 (05): : 467 - 471
- [5] Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia [J]. LARYNGOSCOPE, 2018, 128 (10): : 2234 - 2236
- [7] Tranexamic Acid and Bevacizumab in Hereditary Hemorrhagic Telangiectasia Patients Presenting With Epistaxis [J]. CUTIS, 2013, 91 (04): : 173 - 174
- [8] Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia [J]. LARYNGOSCOPE, 2019, 129 (10): : 2210 - 2215
- [9] Cauterization for epistaxis in hereditary hemorrhagic telangiectasia [J]. B-ENT, 2016, 12 (01): : 9 - 16
- [10] EPISTAXIS DUE TO HEREDITARY HEMORRHAGIC TELANGIECTASIA [J]. LARYNGOSCOPE, 1995, 105 (04): : 445 - 446